(NASDAQ: NPCE) Neuropace's forecast annual revenue growth rate of 16.17% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.6%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.39%.
Neuropace's revenue in 2026 is $98,836,000.On average, 11 Wall Street analysts forecast NPCE's revenue for 2026 to be $3,497,986,763, with the lowest NPCE revenue forecast at $3,330,141,063, and the highest NPCE revenue forecast at $3,625,673,063. On average, 11 Wall Street analysts forecast NPCE's revenue for 2027 to be $4,317,650,426, with the lowest NPCE revenue forecast at $3,888,597,001, and the highest NPCE revenue forecast at $4,601,512,172.
In 2028, NPCE is forecast to generate $5,368,316,454 in revenue, with the lowest revenue forecast at $4,907,684,697 and the highest revenue forecast at $5,766,478,032.